Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | X3M3D | IM / LA |
a patient received Priorix intramuscular instead of subcutaneously; Priorix received to patient 78 year old; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 78-year-old female patient who received MMR (Priorix) (batch number X3M3D, expiry date 01-APR-2025) for prophylaxis. On 27-MAR-2025, the patient received Priorix (intramuscular, left arm) .5 ml. On 27-MAR-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: a patient received Priorix intramuscular instead of subcutaneously) and inappropriate age at vaccine administration (Verbatim: Priorix received to patient 78 year old). The outcome of the subcutaneous injection formulation administered by other route and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 31-MAR-2025 On 27 MAR 2025, a patient received Priorix intramuscularly instead of subcutaneously which led to Subcutaneous injection formulation administered by other route. The patient was 78 year old female and received Priorix which led to Inappropriate age at vaccine administration.